Clinical Trial Update: Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and immunogenicity of a recombinant AMA1-DiCo malaria vaccine formulated with GLA-SE and Alhydrogel in malaria-exposed Afric…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmodium Falciparum Malaria

Drugs mentioned

• AMA1-DiCo malaria vaccine (AMA1-DiCo recombinant Plasmodium falciparum malaria vaccine)

Snippet

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Conditions: Malaria, Falciparum | Phase 1 | Status: COMPLETED